JBH:ASXJB Hi-Fi Limited Analysis
Data as of 2026-06-12 - not real-time
A$77.24
Latest Price
6/10Risk
Risk Level: Medium
Executive Summary
JB Hi‑Fi’s shares are currently trading at about AUD 77, well under the DCF‑derived fair value of roughly AUD 82, indicating a modest discount. The price sits below the 20‑day, 50‑day and 200‑day simple moving averages, a classic bearish signal. Yet the MACD histogram is positive and the MACD line sits above its signal, pointing to emerging momentum. The 14‑day RSI hovers in the low‑to‑mid 60s, suggesting strength without being overbought. Technical support near AUD 67 and resistance around AUD 78 frame the near‑term range, with the current price flirting with the upper bound. Volume has been rising, reinforcing the price action.
Fundamentals show 7.3% revenue growth, a 4.4% trailing EPS and a solid 4.08% dividend yield backed by a 62% payout ratio. Operating cash flow exceeds half a billion dollars, providing ample coverage for the dividend. The market assigns a forward P/E of ~16.8, modest for the sector, and analysts (16 of them) rate the stock as a “buy”. Recent commentary notes the company’s resilience despite a tough retail environment, underscoring its diversified product mix and service offerings. The combination of an undervalued price, attractive yield and steady cash generation makes the stock a compelling value‑oriented play. With an estimated upside of about 6% and limited downside risk, the investment case remains intact.
Fundamentals show 7.3% revenue growth, a 4.4% trailing EPS and a solid 4.08% dividend yield backed by a 62% payout ratio. Operating cash flow exceeds half a billion dollars, providing ample coverage for the dividend. The market assigns a forward P/E of ~16.8, modest for the sector, and analysts (16 of them) rate the stock as a “buy”. Recent commentary notes the company’s resilience despite a tough retail environment, underscoring its diversified product mix and service offerings. The combination of an undervalued price, attractive yield and steady cash generation makes the stock a compelling value‑oriented play. With an estimated upside of about 6% and limited downside risk, the investment case remains intact.
Market Outlook
Short Term
< 1 yearNeutral
Model confidence: 6/10
Key Factors
- Price near resistance with bearish SMA alignment
- Positive MACD momentum despite overall downtrend
- Rising volume supporting short‑term moves
Medium Term
1–3 yearsPositive
Model confidence: 7/10
Key Factors
- DCF valuation indicates ~6% upside
- Strong dividend yield and sustainable payout
- Analyst consensus of “buy” and forward earnings growth
Long Term
> 3 yearsPositive
Model confidence: 8/10
Key Factors
- Resilient business model with diversified product and service mix
- Robust operating and free cash flow generation
- Consistent dividend policy supported by solid balance sheet
Key Metrics & Analysis
Financial Health
Revenue Growth7.30%
Profit Margin4.40%
P/E Ratio17.6
ROE29.24%
ROA10.69%
Debt/Equity43.39
P/B Ratio5.0
Op. Cash FlowA$665.1M
Free Cash FlowA$519.5M
Technical Analysis
TrendBearish
RSI60.8
SupportA$67.38
ResistanceA$78.12
MA 20A$72.82
MA 50A$74.11
MA 200A$90.91
MACDBullish
VolumeIncreasing
Fear & Greed Index88.89
Valuation
Fair ValueA$82.41
Target PriceA$81.88
Upside/Downside6.00%
GradeUndervalued
TypeBlend
Dividend Yield4.08%
Risk Assessment
Beta0.41
Volatility37.08%
Sector RiskHigh
Reg. RiskLow
Geo RiskMedium
Currency RiskLow
Liquidity RiskLow
Similar Tickers
This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.